[AFMD] Affimed N.V.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.85 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart AFMD

Refresh chart

Strongest Trends Summary For AFMD

AFMD is in the medium-term down -28% below S&P in 7 months. In the long-term down -50% below S&P in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate includes AFM13, a natural killer cell bispecific antibody (TandAb) that has completed a Phase I clinical trial for the treatment of certain CD30-positive (CD30+) B- and T-cell malignancies, including hodgkin lymphoma. The company?s product candidates also comprise AFM11, a T-cell TandAb for the treatment of certain CD19+ B-cell malignancies, including non-hodgkin lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia; and AFM21, a TandAb program in preclinical development that binds epidermal growth factor receptor variant III for solid tumors, as well as for patients with glioblastoma, hormone refractory prostate cancer, and head and neck cancer. Affimed Therapeutics B.V. has license agreements with Amphivena Therapeutics, Inc. to develop a product candidate for hematologic malignancies; and Xoma Ireland Limited to conduct research on immunoglobulins. The

Fundamental Ratios
Shares Outstanding EPS-0.9 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-2.22
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-222.01% ROE13.62% ROI
Current Ratio0.26 Quick Ratio0.26 Long Term Debt/Equity Debt Ratio-0.19
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities-40 K Cash From Operating Activities-3.92 M Gross Profit
Net Profit-1.48 M Operating Profit-2 M Total Assets39.29 M Total Current Assets38.29 M
Total Current Liabilities4.13 M Total Debt4.51 M Total Liabilities8.64 M Total Revenue2.54 M
Technical Data
High 52 week4.67 Low 52 week2.27 Last close2.27 Last change-2.99%
RSI24.43 Average true range0.18 Beta1.46 Volume378.6 K
Simple moving average 20 days-16.04% Simple moving average 50 days-22.14% Simple moving average 200 days-28.94%
Performance Data
Performance Week-2.99% Performance Month-18.93% Performance Quart-18.93% Performance Half-24.33%
Performance Year-48.29% Performance Year-to-date-27.01% Volatility daily3.77% Volatility weekly8.43%
Volatility monthly17.27% Volatility yearly59.84% Relative Volume414.03% Average Volume576.16 K
New High New Low

News

2020-05-29 08:05:00 | Affimed Highlights Study Design of its AFM13 REDIRECT Trial at the ASCO 2020 Virtual Meeting

2020-05-28 05:00:00 | Affimed to Present at the Jefferies Virtual Healthcare Conference

2020-05-15 05:00:00 | Affimed Announces Abstracts on Innate Cell Engagers from its ROCK® Platform Accepted for Presentation at AACR Virtual Annual Meeting II

2020-05-03 08:12:15 | Downgrade: Here's How Analysts See Affimed N.V. NASDAQ:AFMD Performing In The Near Term

2020-05-01 08:07:04 | Earnings Update: Affimed N.V. NASDAQ:AFMD Just Reported And Analysts Are Trimming Their Forecasts

2020-04-29 12:00:04 | All You Need to Know About Affimed N.V. AFMD Rating Upgrade to Buy

2020-04-29 07:13:07 | Edited Transcript of AFMD earnings conference call or presentation 28-Apr-20 12:30pm GMT

2020-04-28 18:31:10 | Affimed N.V. AFMD Q4 2019 Earnings Call Transcript

2020-04-28 08:30:41 | Affimed: Q4 Earnings Insights

2020-04-28 06:35:00 | Affimed Reports 2019 Financial Results and Recent Operational Progress

2020-04-16 07:30:00 | Affimed Announces First Patient Successfully Dosed in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of Advanced EGFR-Expressing Solid Tumors Including Colon, Lung and Other Cancers

2020-04-02 07:57:45 | The Daily Biotech Pulse: Novartis Scraps Deal To Sell Sandoz Assets, Nevro Pre-Announces Q1 Shortfall, Affimed Granted Orphan Drug Designation

2020-04-02 06:30:00 | Affimed Provides COVID-19-Related Business Update and Announces Full Year 2019 Financial Results Conference Call on April 28, 2020

2020-04-01 16:01:00 | Affimed Announces FDA Granted Orphan Drug Designation for Lead Innate Cell Engager AFM13 for the Treatment of T-cell Lymphoma

2020-03-26 07:30:00 | Affimed Announces Participation at Upcoming Virtual Investor Conferences

2020-03-24 16:00:00 | Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies

2020-03-17 07:30:00 | Affimed Announces Appointment of Arndt Schottelius, M.D. Ph.D. as Chief Scientific Officer

2020-02-19 07:30:00 | Affimed to Present at the SVB Leerink 9th Annual Global Healthcare Conference

2020-02-03 07:30:00 | Affimed Mourns Passing of Chief Financial Officer Dr. Florian Fischer

2020-01-10 06:30:00 | Affimed Announces Appointment of Andreas Harstrick, M.D., as Chief Medical Officer

2019-12-17 07:30:00 | Affimed Announces Addition to NASDAQ Biotechnology Index

2019-12-14 20:40:21 | Is Affimed NV AFMD Going to Burn These Hedge Funds?

2019-11-27 08:08:01 | New Strong Sell Stocks for November 27th

2019-11-27 07:40:50 | Edited Transcript of AFMD earnings conference call or presentation 19-Nov-19 1:30pm GMT

2019-11-23 06:54:02 | Affimed N.V. Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

2019-11-19 08:45:01 | Affimed N.V. AFMD Reports Q3 Loss, Misses Revenue Estimates

2019-11-19 07:30:00 | Affimed Reports Third Quarter 2019 Financial Results and Recent Operational Progress

2019-11-17 08:42:54 | The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down

2019-11-14 06:30:00 | Affimed to Present at the Jefferies 2019 London Healthcare Conference

2019-11-14 06:30:00 | Affimed Announces Third Quarter 2019 Financial Results and Corporate Update Conference Call on November 19, 2019

2019-11-13 16:10:00 | Affimed Announces Closing of Public Offering of Common Shares and Exercise of Underwriters’ Option to Purchase Additional Shares

2019-11-08 08:14:09 | The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut

2019-11-08 06:30:00 | Affimed Announces Pricing of Public Offering of Common Shares

2019-11-07 16:11:49 | Affimed Announces Proposed Public Offering of Common Shares

2019-11-07 16:01:00 | Affimed Highlights Progress on NK Cell Engager Collaboration with Genentech

2019-11-07 16:01:00 | Affimed Announces FDA Clearance of IND to Commence First-in-Human Phase 1/2a Study of AFM24 for the Treatment of EGFR-Expressing Cancers

2019-10-30 10:33:02 | Affimed N.V. AFMD May Report Negative Earnings: Know the Trend Ahead of Q3 Release

2019-10-19 08:23:22 | Imagine Owning Affimed NASDAQ:AFMD And Wondering If The 35% Share Price Slide Is Justified

2019-10-15 06:30:00 | Affimed Reports Progress on Key Clinical Development Programs

2019-09-04 11:52:32 | Is Affimed NASDAQ:AFMD Using Debt Sensibly?

2019-08-28 05:00:00 | Affimed to Participate in Investor Conferences in September

2019-08-09 19:45:01 | Affimed N.V. AFMD Q2 2019 Earnings Call Transcript

2019-08-07 19:17:06 | Edited Transcript of AFMD earnings conference call or presentation 7-Aug-19 12:30pm GMT

2019-08-07 09:05:01 | Affimed N.V. AFMD Reports Q2 Loss, Misses Revenue Estimates

2019-08-07 07:30:00 | Affimed Reports Second Quarter 2019 Financial and Operational Results

2019-08-06 14:16:34 | Earnings Outlook For Affimed

2019-07-31 05:00:00 | Affimed Announces Second Quarter 2019 Financial Results and Corporate Update Conference Call on August 7, 2019

2019-07-18 13:03:32 | Is Affimed N.V.'s NASDAQ:AFMD CEO Salary Justified?

2019-07-02 09:00:01 | All You Need to Know About Affimed N.V. AFMD Rating Upgrade to Buy

2019-07-01 05:00:00 | Affimed Added to the Russell 2000®, 3000® and Microcap Indexes